华西口腔医学杂志
華西口腔醫學雜誌
화서구강의학잡지
WEST CHINA JOURNAL OF STOMATOLOGY
2014年
5期
441-445
,共5页
凌彬%陈曼丽%刘洁%尹小朋%林兆全%龚忠诚
凌彬%陳曼麗%劉潔%尹小朋%林兆全%龔忠誠
릉빈%진만려%류길%윤소붕%림조전%공충성
普萘洛尔%增殖期婴幼儿血管瘤%血管内皮生长因子-A%表皮生长因子样结构域7
普萘洛爾%增殖期嬰幼兒血管瘤%血管內皮生長因子-A%錶皮生長因子樣結構域7
보내락이%증식기영유인혈관류%혈관내피생장인자-A%표피생장인자양결구역7
propranolol%proliferating infantile haemangioma%vascular endothelial growth factor-A%epidermal growth factor-like domain 7
目的：对普萘洛尔治疗增殖期婴幼儿血管瘤的临床疗效和治疗过程中血清及尿液血管内皮生长因子-A （VEGF-A）和表皮生长因子样结构域7（EGFL7）表达水平进行检测分析。方法选择30例婴幼儿增殖期血管瘤患者为研究对象，口服普萘洛尔治疗4~8个月，口服剂量为每天0.5~2mg·kg-1。采用B超测量治疗前后瘤体的半径，采用Achauer疗效评定法进行临床疗效评估。采用酶联免疫吸附法（ELISA）检测治疗前、治疗后4周、治疗后12周血清及尿液中VEGF-A和EGFL7水平。结果治疗效果评价：2例优，11例好，14例中等，3例差。治疗前血清VEGF-A水平最高（335.692pg·mL-1±136.146pg·mL-1），治疗后4周（264.853pg·mL-1±122.120pg·mL-1）和治疗后12周（211.345pg·mL-1±104.035pg·mL-1）呈逐渐下降趋势，治疗后4、12周血清VEGF-A水平低于治疗前（P<0.05）。治疗前尿液VEGF-A水平最高（76.234pg·mL-1±24.169pg·mL-1），治疗后4周（56.454pg·mL-1±16.111pg·mL-1）和治疗后12周（34.728pg·mL-1±12.656pg·mL-1）呈逐渐下降趋势，治疗后4、12周尿液VEGF-A水平低于治疗前（P<0.05）。血清和尿液中EGFL7的表达趋势与VEGF-A一致。结论普萘洛尔能够安全有效地治疗增殖期婴幼儿血管瘤。普萘洛尔能降低增殖期婴幼儿血管瘤患者外周血清和尿液中VEGF-A和EGFL7水平。
目的：對普萘洛爾治療增殖期嬰幼兒血管瘤的臨床療效和治療過程中血清及尿液血管內皮生長因子-A （VEGF-A）和錶皮生長因子樣結構域7（EGFL7）錶達水平進行檢測分析。方法選擇30例嬰幼兒增殖期血管瘤患者為研究對象，口服普萘洛爾治療4~8箇月，口服劑量為每天0.5~2mg·kg-1。採用B超測量治療前後瘤體的半徑，採用Achauer療效評定法進行臨床療效評估。採用酶聯免疫吸附法（ELISA）檢測治療前、治療後4週、治療後12週血清及尿液中VEGF-A和EGFL7水平。結果治療效果評價：2例優，11例好，14例中等，3例差。治療前血清VEGF-A水平最高（335.692pg·mL-1±136.146pg·mL-1），治療後4週（264.853pg·mL-1±122.120pg·mL-1）和治療後12週（211.345pg·mL-1±104.035pg·mL-1）呈逐漸下降趨勢，治療後4、12週血清VEGF-A水平低于治療前（P<0.05）。治療前尿液VEGF-A水平最高（76.234pg·mL-1±24.169pg·mL-1），治療後4週（56.454pg·mL-1±16.111pg·mL-1）和治療後12週（34.728pg·mL-1±12.656pg·mL-1）呈逐漸下降趨勢，治療後4、12週尿液VEGF-A水平低于治療前（P<0.05）。血清和尿液中EGFL7的錶達趨勢與VEGF-A一緻。結論普萘洛爾能夠安全有效地治療增殖期嬰幼兒血管瘤。普萘洛爾能降低增殖期嬰幼兒血管瘤患者外週血清和尿液中VEGF-A和EGFL7水平。
목적：대보내락이치료증식기영유인혈관류적림상료효화치료과정중혈청급뇨액혈관내피생장인자-A （VEGF-A）화표피생장인자양결구역7（EGFL7）표체수평진행검측분석。방법선택30례영유인증식기혈관류환자위연구대상，구복보내락이치료4~8개월，구복제량위매천0.5~2mg·kg-1。채용B초측량치료전후류체적반경，채용Achauer료효평정법진행림상료효평고。채용매련면역흡부법（ELISA）검측치료전、치료후4주、치료후12주혈청급뇨액중VEGF-A화EGFL7수평。결과치료효과평개：2례우，11례호，14례중등，3례차。치료전혈청VEGF-A수평최고（335.692pg·mL-1±136.146pg·mL-1），치료후4주（264.853pg·mL-1±122.120pg·mL-1）화치료후12주（211.345pg·mL-1±104.035pg·mL-1）정축점하강추세，치료후4、12주혈청VEGF-A수평저우치료전（P<0.05）。치료전뇨액VEGF-A수평최고（76.234pg·mL-1±24.169pg·mL-1），치료후4주（56.454pg·mL-1±16.111pg·mL-1）화치료후12주（34.728pg·mL-1±12.656pg·mL-1）정축점하강추세，치료후4、12주뇨액VEGF-A수평저우치료전（P<0.05）。혈청화뇨액중EGFL7적표체추세여VEGF-A일치。결론보내락이능구안전유효지치료증식기영유인혈관류。보내락이능강저증식기영유인혈관류환자외주혈청화뇨액중VEGF-A화EGFL7수평。
Objective This study aims to investigate the expression levels of serum and urinary vascular endothelial growth factor-A (VEGF-A) and epidermal growth factor-like domain 7 (EGFL7) in proliferating infantile hemangioma patients under propranolol treatment. Methods Propranolol (0.5-2 mg·kg-1) was orally administered to 30 infants every day for 4-8 months. The Achauer method was used to measure the tumor radius and thus evaluate the clinical curative effects of the treatment. Enzyme-linked immunosorbent assay was used to measure the serum and urinary concentrations of VEGF-A and EGFL7 at 0, 4, and 12 weeks after the treatment. Results The treatment response was excellent in 2 patients, good in 11, moderate in 14, and poor in 3. Serum VEGF-A (335.692 pg·mL-1±136.146 pg·mL-1) was high before the treatment and then significantly decreased after 4 weeks (264.853 pg·mL-1± 122.120 pg·mL-1) and 12 weeks (211.345 pg·mL-1± 104.035 pg·mL-1) of treatment (P<0.05). Urinary VEGF-A (76.234 pg·mL-1±24.169 pg·mL-1) was high before the treatment and then significantly decreased after four weeks (56.454 pg·mL-1±16.111 pg·mL-1) and twelve weeks (34.728 pg·mL-1±12.656 pg·mL-1) of treatment (P<0.05). Serum and urinary EGFL7 also decreased after the treatment, showing a positive relationship with VEGF-A. Conclusion Propranolol can be safely and effectively used to treat prolife-rating infantile hemangiomas. This treatment can reduce the peripheral serum and urinary concentrations of VEGF-A and EGFL7 in affected children.
